Literature DB >> 16373632

Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.

Carlos A Molina1, Marc Ribo, Marta Rubiera, Joan Montaner, Esteban Santamarina, Raquel Delgado-Mederos, Juan F Arenillas, Rafael Huertas, Francisco Purroy, Pilar Delgado, José Alvarez-Sabín.   

Abstract

BACKGROUND AND
PURPOSE: We sought to evaluate the effects of administration of microbubbles (MBs) on the beginning, speed, and degree of middle cerebral artery (MCA) recanalization during systemic thrombolysis and continuous 2-MHz pulsed-wave transcranial Doppler (TCD) monitoring.
METHODS: We evaluated 111 patients with acute stroke attributable to MCA occlusion treated with intravenous tissue plasminogen activator (tPA). Thirty-eight patients were treated with tPA plus continuous 2-hour TCD monitoring plus 3 doses of 2.5 g (400 mg/mL) of galactose-based MBs given at 2, 20, and 40 minutes after tPA bolus (MB group). These patients were compared with 73 patients who were allocated to receive tPA plus continuous 2-hour TCD ultrasound (US) monitoring (tPA/US group) or tPA plus placebo monitoring (tPA group), most of whom were enrolled in a previous study of US-enhanced thrombolysis. The beginning, degree, and time to maximum completeness of recanalization during the first 2 hours of tPA bolus were recorded.
RESULTS: Median prebolus National Institutes of Health Stroke Scale (NIHSS) score was 18. Eighty patients (72%) had a proximal and 31 (28%) a distal MCA occlusion on TCD. Thirty-seven patients (33%) received tPA/US, 38 (34%) received tPA/US/MB, and 36 (32%) were treated with tPA alone. Stroke severity, time to treatment, location of MCA occlusion, and presence of carotid artery disease were similar among groups. Two-hour recanalization was seen in 14 (39%), 25 (68%), and 27 patients (71%) in the tPA, tPA/US, and tPA/US/MB groups, respectively (P=0.004). Two-hour complete recanalization rate was significantly (P=0.038) higher in the tPA/US/MB group (54.5%) compared with tPA/US (40.8%) and tPA (23.9%) groups. The time to beginning of recanalization after tPA bolus was 26+/-18 minutes in the tPA/US group and 19+/-12 minutes in the tPA/US/MB group (P=0.12). Four patients (3.6%) experienced symptomatic intracranial hemorrhage: 2 (5.5%), 1 (2.7%), and 1 patient (2.6%) who received tPA only, tPA/US, and tPA/US/MB, respectively, experienced symptomatic intracranial hemorrhage. At 24 hours, 31%, 41%, and 55% of tPA, tPA/US, and tPA/US/MB improved >4 points in the NIHSS score.
CONCLUSIONS: Administration of MBs induces further acceleration of US-enhanced thrombolysis in acute stroke, leading to a more complete recanalization and to a trend toward better short- and long-term outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16373632     DOI: 10.1161/01.STR.0000199064.94588.39

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  119 in total

1.  Combined contrast-enhanced ultrasound and rt-PA treatment is safe and improves impaired microcirculation after reperfusion of middle cerebral artery occlusion.

Authors:  Max Nedelmann; Nouha Ritschel; Simone Doenges; Alexander C Langheinrich; Till Acker; Peter Reuter; Mesut Yeniguen; Jan Pukropski; Manfred Kaps; Clemens Mueller; Georg Bachmann; Tibo Gerriets
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-09       Impact factor: 6.200

Review 2.  Ultrasound- and microspheres-enhanced thrombolysis for stroke treatment: state of the art.

Authors:  Clotilde Balucani; Andrei V Alexandrov
Journal:  Curr Cardiol Rep       Date:  2010-01       Impact factor: 2.931

Review 3.  Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials?

Authors:  H Bart van der Worp; Malcolm R Macleod; Rainer Kollmar
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-31       Impact factor: 6.200

4.  Selective and self-guided micro-ablation of tissue with plasmonic nanobubbles.

Authors:  Ekaterina Y Lukianova-Hleb; Irina I Koneva; Alexander O Oginsky; Saverio La Francesca; Dmitri O Lapotko
Journal:  J Surg Res       Date:  2010-11-26       Impact factor: 2.192

Review 5.  [Thrombolysis for ischemic stroke: an update].

Authors:  M Köhrmann; E Jüttler; H B Huttner; P D Schellinger
Journal:  Nervenarzt       Date:  2007-04       Impact factor: 1.214

6.  Sonothrombolysis: an emerging modality for the treatment of acute ischemic and hemorrhagic stroke.

Authors:  Azita Soltani; Wayne M Clark; Douglas R Hansmann
Journal:  Transl Stroke Res       Date:  2011-04-15       Impact factor: 6.829

7.  Integrated Histotripsy and Bubble Coalescence Transducer for Thrombolysis.

Authors:  Aiwei Shi; Jonathan Lundt; Zilin Deng; Jonathan Macoskey; Hitinder Gurm; Gabe Owens; Xi Zhang; Timothy L Hall; Zhen Xu
Journal:  Ultrasound Med Biol       Date:  2018-09-30       Impact factor: 2.998

Review 8.  [Ultrasound contrast agents. Pharmaceutical drug safety and bioeffects].

Authors:  M Krix; J W Jenne
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

9.  Characterization of ultrasound propagation through ex-vivo human temporal bone.

Authors:  Azzdine Y Ammi; T Douglas Mast; I-Hua Huang; Todd A Abruzzo; Constantin-C Coussios; George J Shaw; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2008-05-23       Impact factor: 2.998

10.  Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes.

Authors:  Denise A B Smith; Sampada S Vaidya; Jonathan A Kopechek; Shao-Ling Huang; Melvin E Klegerman; David D McPherson; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2010-01       Impact factor: 2.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.